<DOC>
	<DOCNO>NCT00477035</DOCNO>
	<brief_summary>The purpose study conduct phase I study adoptive immunotherapy autologous , ex-vivo expand cytokine-induced killer ( CIK ) cell reduce relapse rate autologous stem cell transplant patient high-risk hematologic malignancy .</brief_summary>
	<brief_title>Post-transplant Autologous Cytokine-induced Killer ( CIK ) Cells Treatment High Risk Hematologic Malignancies</brief_title>
	<detailed_description>Disease relapse remain major cause treatment failure autologous stem cell transplantation patient high-risk disease . Relapse autologous transplant part due persistence residual cancer cell . Cellular immunotherapy use activate autologous effector cell recognize kill tumor target minimal disease state transplant strategy explore reduce relapse improve survival . We hypothesize cytokine-induced killer ( CIK ) cell-based immunotherapy reduce relapse rate high-risk autologous stem cell transplantation treat post-transplant minimal residual disease .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>Patients 18 75 year age , inclusive candidate standard autologous SCT high risk relapse : Acute myelogenous leukemia ( AML ) , high risk , CR1 beyond without donor ( CR1 define : normal bone marrow morphology , resolution previously abnormal karyotype , neutrophils &gt; 1000/ul , platelet &gt; 100,000/ul , independence red cell transfusion , evidence extramedullary leukemia ) Hodgkin 's lymphoma relapse refractory , presence &gt; = 1 adverse risk factor ( Adverse risk factor define stage IV involvement lung bone marrow , constitutional symptom , presence minimal residual disease preparatory regimen ) Multiple myeloma high risk feature single autologous transplant option . High risk feature define IgA myeloma , B2M &gt; 2.5 mg/ml normal kidney function , complex karyotype isolate chromosome 13 abnormality , standarddose therapy &gt; 12 month , inability achieve least 50 % reduction plasma cell bone marrow 50 % reduction paraprotein concentration initial induction chemotherapy prior transplant . Patients must ECOG performance status &lt; 2 Patients must adequate renal function serum creatinine &lt; 2 mg/dl creatinine clearance &gt; 50 ml/min . Patients must adequate liver function total bilirubin &lt; 2 mg/dl transaminase &lt; 3 time upper limit normal . Patients must negative antibody serology human immunodeficiency virus ( HIV1 2 ) Adult woman minority include . Patients childbearing potential must use effective contraception . Patients must sign informed consent prior initiation studyrelated treatment . ECOG performance status &gt; 2 LVEF &lt; 45 % Pulmonary diffusion capacity &lt; 50 % predict Total bilirubin &gt; 2 mg/dl Creatinine &gt; 2 mg/dl Pregnancy Patients positive HIV Patients engraftment failure day 42 post transplant define failure achieve granulocyte count &gt; 500/ul 3 successive daily determination unsupported platelet count &gt; = 50,000/ul day 42 Patients active , uncontrolled infection expect continue beyond day 4263 . Patients fail collect sufficient quantity stem cell ( &gt; 1.6 x 10^9 cell ) apheresis support CIK cell expansion culture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>